Copertina

Erratum to “Evaluation of efficiency and effectiveness of different recruitment strategies for the FINGER‐NL multidomain lifestyle intervention trial via the Dutch Brain Research Registry”

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Alzheimer's & Dementia: Translational Research & Clinical Interventions
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Effects of multidomain intervention on cognitive function in older adults with cognitive impairment: A multicenter, four‐arm, cluster randomized trial
di: Zhaoxue Yin, et al.
Pubblicazione: (2026)

A service‐oriented approach to clinical trial recruitment for dementia and brain health: Methods and case examples of MyAlliance for Brain Health
di: Eric D. Vidoni, et al.
Pubblicazione: (2024)

Digital efforts in Spanish for enrolling Latino adults in the Brain Health Registry
di: Miriam T. Ashford, et al.
Pubblicazione: (2025)

Using concept mapping to identify recruitment and engagement strategies for inclusion of LGBTQIA+ populations in Alzheimer's disease and related dementia research
di: Brittany Klenczar‐Castro, et al.
Pubblicazione: (2024)

Researcher photographs in recruitment materials to increase willingness to participate in brain health research
di: Christy J. W. Ledford, et al.
Pubblicazione: (2026)

Weight loss and metabolic improvements dominate the microbiome response in the MIND diet intervention: a randomized controlled trial
di: Robin M. Voigt, et al.
Pubblicazione: (2026)

Cost‐effectiveness of a multicomponent intervention against cognitive decline
di: Christian Brettschneider, et al.
Pubblicazione: (2025)

Implications of practice effects for the design of Alzheimer clinical trials
di: Jasmin A. Duehring, et al.
Pubblicazione: (2025)

Comparison of sample characteristics of Wisconsin Alzheimer's Disease Research Center participants with the Wisconsin state population—An evaluation of the recruitment effort
di: Yue Ma, et al.
Pubblicazione: (2025)

Perspective: Minimal clinically important difference (MCID) and Alzheimer's disease clinical trials
di: Jeffrey Cummings
Pubblicazione: (2025)

Blood biomarkers for Alzheimer's disease are correlated with measures of agitation and cognition in a randomized trial assessing the effects of escitalopram on agitation
di: Maansi Barnwal, et al.
Pubblicazione: (2026)

Utilizing MCID for evaluating clinical relevance of AD therapeutic interventions
di: Jamie L. Hamilton, et al.
Pubblicazione: (2025)

Biomarkers in Alzheimer's disease clinical trials: 2025
di: Amanda M. Leisgang Osse, et al.
Pubblicazione: (2026)

Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerations: Proceedings from the Alzheimer's Association Research Roundtable (AARR) Fall 2021 meeting
di: Ronald C. Petersen, et al.
Pubblicazione: (2025)

Machine learning–enhanced screening funnel for clinical trials in Alzheimer's disease
di: Scott Gladstein, et al.
Pubblicazione: (2025)

A mindfulness‐based multicomponent caregiver intervention (PAACC): objectives, study design, and cohort description
di: Mamta Sapra, et al.
Pubblicazione: (2025)

Comprehensive intervention combining group and personalized language therapy in primary progressive aphasia: Quantitative and qualitative findings
di: Tijana Simic, et al.
Pubblicazione: (2025)

Effects of care partner type on outcomes from a multicomponent behavioral intervention for mild cognitive impairment
di: Zhigang Xie, et al.
Pubblicazione: (2026)

Clinically meaningful outcomes in Alzheimer's disease and Alzheimer's disease related dementias trials
di: Luke E. Stoeckel, et al.
Pubblicazione: (2025)

A common outcome set for trials in dementia with Lewy bodies (DLB COS)
di: Joseph P. M. Kane, et al.
Pubblicazione: (2025)

Assessing safety and efficacy in subpopulations in Alzheimer's disease clinical trials: contextualizing representativeness
di: Guogen Shan, et al.
Pubblicazione: (2025)

Impact of study partner replacement in a mild cognitive impairment clinical trial
di: Lucy A. Dolmadjian, et al.
Pubblicazione: (2025)

Recruitment and eligibility in a Phase 1 early Alzheimer's disease trial of Sabirnetug
di: Robyn Moxon, et al.
Pubblicazione: (2025)

Mapping brain change longitudinally: physical activity intervention reshapes structural alterations and functional connectivity in Alzheimer's disease
di: Ravi Dadsena, et al.
Pubblicazione: (2026)

ACE trial design: Equol targeting estrogen receptor‐β in vascular and cognitive aging
di: Akira Sekikawa, et al.
Pubblicazione: (2025)

Assessing clinical meaningfulness in clinical trials for Alzheimer's disease: A U.S. regulatory perspective
di: Teresa Buracchio, et al.
Pubblicazione: (2025)

Brain networks modulating the relationship between white matter volume and cognition
di: Osamu Katayama, et al.
Pubblicazione: (2026)

Leveraging recent advances in plasma biomarkers to optimize early proof of concept trials in Alzheimer's disease
di: Garrett B. Duncan, et al.
Pubblicazione: (2025)

Functional connectome metrics reveal distinct prognostic subtypes in two Phase 3 gantenerumab trials
di: Susanna Gobbi, et al.
Pubblicazione: (2026)

Blood‐based biomarker prescreening with different testing combinations and cutoffs: A simulation study examining efficacy and cost‐effectiveness in Alzheimer's disease prevention studies
di: Kenichiro Sato, et al.
Pubblicazione: (2025)

Health and Aging Brain Study–Health Disparities (HABS‐HD) methods and partner characteristics
di: Melissa E. Petersen, et al.
Pubblicazione: (2025)

Cognitive training, alone and combined with acetylcholinesterase inhibitors, in neurocognitive disorders: long‐term efficacy and the role of cognitive reserve on 30 months of intervention
di: Adele Ravelli, et al.
Pubblicazione: (2026)

Critical evaluation of real‐world evidence of repurposable medicines in the Alzheimer's disease drug development pipeline using a target trial emulation
di: Reina Tonegawa‐Kuji, et al.
Pubblicazione: (2025)

Incorporating individually defined brain health priorities in clinical trial outcomes: the electronic Person‐Specific Outcome Measure approach in the United States
di: Stina Saunders, et al.
Pubblicazione: (2025)

Generating real‐world evidence in early Alzheimer's disease: Considerations for applying the target trial emulation framework to study the safety of anti‐amyloid therapies
di: Xiaojuan Li, et al.
Pubblicazione: (2025)

Recruitment of mid‐life adults to a randomized clinical trial: The multicultural healthy diet study to reduce cognitive decline and Alzheimer's disease risk
di: Mindy J. Katz, et al.
Pubblicazione: (2025)

Designing and implementing the IDEAL Study: A randomized clinical trial of APOE genotype disclosure for late‐onset Alzheimer's disease in an urban Latino population
di: John B. Wetmore, et al.
Pubblicazione: (2024)

The I‐Learn Cognition and Behavior program for non‐pharmacological treatment of agitation in nursing home residents with neurocognitive disorders: A cluster randomized trial
di: Céline Lourdel, et al.
Pubblicazione: (2026)

Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo‐controlled trials of semaglutide in participants with early‐stage symptomatic Alzheimer's disease
di: Philip Scheltens, et al.
Pubblicazione: (2026)

Identification of cerebrospinal fluid pharmacodynamic biomarkers and molecular correlates of brain activity in a Phase 2 clinical trial of the Alzheimer's disease drug candidate CT1812
di: Valentina Di Caro, et al.
Pubblicazione: (2025)